l-thyroxin berlin-chemie 50 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 50 μg
l-thyroxin berlin-chemie 125 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 125 μg
l-thyroxin berlin-chemie 75 mikrogramu tabletes
berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 75 μg
certican 0,25 mg tabletes
novartis baltics, sia, latvia - everolims - tablete - 0,25 mg
certican 0,5 mg tabletes
novartis baltics, sia, latvia - everolims - tablete - 0,5 mg
certican 1,0 mg tabletes
novartis baltics, sia, latvia - everolims - tablete - 1,0 mg
certican 0,25 mg disperģējamās tabletes
novartis baltics, sia, latvija - everolims - disperģējamā tablete - 0,25 mg
certican 0,1 mg disperģējamās tabletes
novartis baltics, sia, latvija - everolims - disperģējamā tablete - 0,1 mg
certican 0,75 mg tabletes
novartis baltics, sia, latvia - everolims - tablete - 0,75 mg
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastiski līdzekļi - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.